Cargando…
Tazemetostat: EZH2 Inhibitor
Epigenetic regulation is a novel approach to cancer treatment. Inhibition of enhancer of zeste homolog 2 (EZH2) is a method to provide targeted epigenetic regulation. Tazemetostat is a first-in-class targeted epigenetic regulator that specifically inhibits EZH2. This new FDA-approved oral treatment...
Autores principales: | Straining, Rachael, Eighmy, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Harborside Press LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955562/ https://www.ncbi.nlm.nih.gov/pubmed/35369397 http://dx.doi.org/10.6004/jadpro.2022.13.2.7 |
Ejemplares similares
-
Teclistamab-cqyv: The First Bispecific T-Cell Engager Antibody for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
por: Hua, Gwen, et al.
Publicado: (2023) -
Ivosidenib: IDH1 Inhibitor for the Treatment of Acute Myeloid Leukemia
por: Merchant, Shelby L., et al.
Publicado: (2019) -
A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019) -
Glasdegib: A Novel Hedgehog Pathway Inhibitor for Acute Myeloid Leukemia
por: Thompson, Daniel L., et al.
Publicado: (2020) -
A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies
por: Moore, Donald C., et al.
Publicado: (2021)